Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 5 IN PLASTIC CONTAINER versus AMINOSYN II 7 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 5 IN PLASTIC CONTAINER versus AMINOSYN II 7 W ELECTROLYTES.
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER vs AMINOSYN II 7% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% w/ Dextrose 5% provides essential and non-essential amino acids for protein synthesis and dextrose for caloric support, aiding in nitrogen balance and maintenance of lean body mass in parenteral nutrition.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
Intravenous infusion. Adult dose: 500-1000 mL per day, infused at a rate not exceeding 100 mL/hour, adjusted based on metabolic requirements and tolerance.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
None Documented
None Documented
Not applicable as a single entity; amino acids and dextrose are endogenous substances. Metabolic half-life of infused amino acids ~10-30 min; dextrose ~15-20 min. Continuous infusion results in steady state.
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
Renal excretion of amino acids and dextrose metabolites (CO2, water). Urea nitrogen accounts for ~80-90% of nitrogen excretion. Unchanged dextrose minimal (<1%). Biliary/fecal excretion negligible.
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution